Humedics successfully closed its first VC-financing round with Charité Biomedical Fund, VC Fonds Technologie , KfW, HTGF and Ventegis Capital AG
Humedics has developed a breath test (LiMAxTM test) based diagnostic system composed of the medical device FLIPTM and a new intravenous diagnostic drug preparation (13C-Methacetin).
More than 100 million people world-wide suffer from chronic liver diseases (i.e. cirrhosis, hepatitis, fatty liver, metabolic disorders and tumors). Evaluating current liver function correctly remains a major challenge for physicians, given that existing tests cannot directly measure liver function quantitatively.
The LiMAxTM test enables the clinician to quantitatively determine the individual liver function capacity within minutes. This allows for deciding on treatment strategies optimally adapted to the individual patients liver status. Current applications include diagnosis of the liver function before and after liver transplantation as well as planning of liver surgeries (for example: How much liver tissue can be extracted without risking post-operative liver failure) and different diseases of the liver such as liver cirrhosis.
The LiMAxTM test was developed at the Charité, Berlin by Dr. M. Stockmann at the Department of General, Visceral, and Transplantation Surgery of Prof. Neuhaus (Charité – University-Medicine, Berlin) and the FLIPTM device by Prof. K. Heyne (Department of Physics, Ultrafast Spectroscopy on Biologically Relevant Systems) at the Free University Berlin.
Up to date the LiMAxTM test has been validated in more than 1.000 patients involving over 5.000 tests and the results have been published in well recognized journals.
Wilfried Heyne; Managing Director of Humedics comments: “We are delighted to have been able to attract this group of experienced MedTech investors including the Charité Biomedical Fund given that Humedics is a “Spin-Off” from Charité and FU-Berlin. The proceeds of this financing will be used to further develop and finalize the FLIPTM / LiMAxTM test-system.”
Dr. Klaus Stöckemann, Chairman of Humedics’ board and Managing Director at Peppermint VenturePartners (the manager of the Charité Biomedical Fund) adds: “We have been following the technology for the last three years and are very happy to work with Humedics and the other co- investors to develop the company towards “the company for personalized medicine for the liver” and make the LiMAxTM test standard of care in liver diagnostics.”
Based in Berlin, Germany, Humedics GmbH is specialised in rapid and accurate liver function measurement using LiMAx®, an innovative technology for analysing exhaled air. The LiMAx® test provides physicians with a method for quantitatively assessing an individual patient’s liver function capacity within minutes. This enables physicians to select treatment strategies and follow disease progression based on up-to-date knowledge of the functional health of the liver.
Current applications, which have already been published in prestigious medical journals, include liver function diagnosis before and after liver transplantation, surgical planning for liver surgery (such as assessing how much liver tissue can be removed without increasing the risk of acute liver failure), and assessment of liver diseases such as fibrosis and cirrhosis. At present, more than 20 studies regarding new indications are being conducted. These include diagnosing and staging of chronic liver diseases such as non-alcoholic steatohepatitis (NASH), as well as selecting, monitoring and managing different oncology treatment options.
These studies, initiated by researchers, have already provided evidence of further potential for the LiMAx® tests. The LiMAx® test is in routine clinical use at more than 30 leading university hospitals in Europe. So far, more than 20,000 LiMAx® tests have been performed. The LiMAx® test is commercially available in Germany, Austria and the UK.